Aptevo Therapeutics Inc.
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 3.51M | 3.29M | 3.38M | 3.44M | 3.86M |
| Gross Profit | -3.51M | -3.29M | -3.38M | -3.44M | -3.86M |
| SG&A Expenses | 10.22M | 10.52M | 11.08M | 11.41M | 11.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.60M | 24.60M | 25.95M | 28.11M | 28.88M |
| Operating Income | -24.60M | -24.60M | -25.95M | -28.11M | -28.88M |
| Income Before Tax | -24.13M | -24.01M | -25.25M | -27.31M | -18.65M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.13 | -24.01 | -25.25 | -27.31 | -18.65 |
| Earnings from Discontinued Operations | -- | 293.00K | 293.00K | 293.00K | 1.24M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.13M | -23.72M | -24.95M | -27.02M | -17.41M |
| EBIT | -24.60M | -24.60M | -25.95M | -28.11M | -28.88M |
| EBITDA | -24.25M | -24.21M | -25.52M | -27.61M | -28.31M |
| EPS Basic | -455.68 | -886.37 | -868.48 | -806.64 | -438.43 |
| Normalized Basic EPS | -284.80 | -567.58 | -556.40 | -517.75 | -287.62 |
| EPS Diluted | -455.69 | -886.45 | -868.55 | -806.71 | -438.50 |
| Normalized Diluted EPS | -284.80 | -567.58 | -556.40 | -517.75 | -287.62 |
| Average Basic Shares Outstanding | 1.22M | 412.30K | 127.20K | 32.10K | 13.50K |
| Average Diluted Shares Outstanding | 1.22M | 412.30K | 127.20K | 32.10K | 13.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |